MENODYS launches the clinical validation of its Tinnitus Assessment Technology

Longueuil, Quebec, Canada – MENODYS is proud to announce the launch of the clinical validation phase of its tinnitus assessment technology.

This important milestone is reached following the successful completion of prototypes enabling the assessment of tinnitus based on the developed university bench version. Invented by Pr Sylvie Hébert and Philippe Fournier of the School of Speech Pathology and Audiology at the University of Montreal, the device will offer audiology specialists around the world a rapid and innovative approach to objectively assess the frequency and amplitude of their patient’s tinnitus. This medical technology will thus allow audiology specialists to precisely design the symptom attenuation protocol for the patient’s tinnitus. The clinical validation will involve adults suffering from tinnitus and will be performed at the department of audiology of the University of Montreal, Quebec, Canada.

“We are excited with the rapid development process of this much needed medical device innovation for an important unmet need in audiology. This clinical validation will confirm the published results of this new technological concept and bring us a step closer to offering this innovation worldwide to tinnitus patients and audiology professionals”, said Richard Côté, Executive Vice President of MENODYS.

Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians, 30 million Americans and more than 120 million Europeans.

MENODYS is a Canadian company specialized in the development and commercialization of medical technologies.